Open |
S2209 |
VRd-Lite versus DRd followedby Len+/-Dara |
5/30/2023 |
|
5% |
|
|
Open |
S2207 |
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment |
6/30/2023 |
|
6% |
|
|
Open |
S2212 |
SCARLET |
7/21/2023 |
|
6% |
|
|
Open |
S2210 |
Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency |
8/14/2023 |
|
2% |
|
|
Open |
S2206 |
A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor… |
10/30/2023 |
|
1% |
|
|
Open |
S2213 |
A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab… |
12/1/2023 |
|
0% |
|
|
Open |
S1900K |
Targeted Treatment for Advanced NSCLC that has a MET Exon 14 Skipping Gene Change |
12/18/2023 |
|
0% |
|
|
Open |
S2303 |
Adding Nivolumab to Usual Treatment for People with Advanced Stomach or Esophageal Cancer |
5/6/2024 |
|
|
|
|